Yazar "Dişel, Umut" seçeneğine göre listele

Listeleniyor 1 - 5 / 5
  • Küçük Resim
    Öğe
    Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours—results from a Turkish multi-centre study
    (2024) Ölmez, Ömer Fatih; Bilici, Ahmet; Er, Özlem; Bişgin, Atıl; Sevinç, Alper; Akman, Tülay; Uslu, Rüçhan; Molinas Mandel, Nil; Yalçın, Şuayib; Teomete, Mehmet; Görümlü, Gürbüz; Demir, Atakan; Namal, Esat; Alıcı, Süleyman; Selçukbiricik, Fatih; Bavbek, Sevil; Paksoy, Fatma; Başaran, Gül; Özer, Leyla; Şener, Nur; Harputluoğlu, Hakan; Kaya, Ali Osman; Yazar, Aziz; Afşar, Çiğdem Usul; Göker, Erdem; Şen, Fatma; Gököz Doğu, Gamze; Şeker, Mesut; Özkan, Metin; Türken, Orhan; Özveren, Ahmet; Orhan, Bülent; Yumuk, Fulden; Üskent, Necdet; Saip, Pınar; Şanlı, Ulus Ali; Dişel, Umut; Berk, Veli; Alakavuklar, Mehmet
    Objective: The objective of this multi-centre, real-world study was to examine the potential influence of comprehensive molecular profiling on the development of treatment decisions or adjustments for patients with advanced solid malignancies. We then evaluated the impact of these informed choices on patient treatment outcomes. Methods: The study encompassed 234 adult patients (mean age: 52.7 ± 14.3 years, 54.7% women) who were diagnosed with solid tumours at 21 different medical centres in Turkey. Remarkably, 67.9% of the patients exhibited metastasis at the time of diagnosis. We utilized an OncoDNA (Gosselies, Belgium) platform (OncoDEEP) integrating next-generation sequencing with additional tests to harvest complex molecular profiling data. The results were analyzed in relation with two specific outcomes: (i) the impact on therapeutic decisions, including formulation or modifications, and (ii) associated treatment response. Results: Out of the 228 patients with final molecular profiling results, 118 (50.4%) had their treatment modified, whilst the remaining 110 (47.0%) did not. The response rates were comparable, with 3.9 versus 3.4% for complete response, 13.6 versus 29.3% for partial response, 66.9 versus 51.7% for progressive disease and 15.5 versus 15.5% for stable disease for treatments informed and not informed by complex molecular profiling, respectively (P = 0.16). Conclusion: Our real-world findings highlight the significant impact of complex molecular profiling on the treatment decisions made by oncologists for a substantial portion of patients with advanced solid tumours. Regrettably, no significant advantage was detected in terms of treatment response or disease control rates.
  • Küçük Resim Yok
    Öğe
    Clinical assessment of HRD scoring in relation to PARPi response in terms of statistical guidance on reporting results for CDx tests evaluation.
    (Lippincott Williams & Wilkins, 2023) Bişgin, Atıl; Boğa, İbrahim; Eskut, Kaan İhsan; Rencüzoğulları, Çağla; Sönmezler, Özge; Köse, Fatih; Beşen, Ali Ayberk; Ölmez, Ömer Fatih; Dişel, Umut; Koçer, Nazım Emrah; Bolat, Filiz; Jinga, Dan-Corneliu; Lazar, Ioana; Pathak, Surajit
    [Abstract Not Available]
  • Küçük Resim
    Öğe
    Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group
    (NLM (Medline), 2022) Gürbüz, Mustafa; Kılıçkap, Saadettin; Bilici, Ahmet; Karadurmuş, Nuri; Sezer, Ahmet; Şendur, Mehmet Ali Nahit; Paydaş, Semra; Artaç, Mehmet; Fulden Yumuk, Perran; Gürsoy, Pınar; Uysal, Mükremin; Şenol Coşkun, Hasan; Tatlı, Ali Murat; Selçukbiricik, Fatih; Dişel, Umut; Köksoy, Elif Berna; Güven, Deniz Can; Uğraklı, Muzaffer; Akkuş, Erman; Yücel, Şebnem; Erol, Cihan; Karakaya, Serdar; Şakalar, Teoman; Khanmammadov, Nijat; Paksoy, Nail; Demirkazık, Ahmet
    Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although small prospective studies showed efficacy and safety of crizotinib in NSCLC with MET alterations, there is limited real-life data. Aim of this study is to investigate real-life efficacy and safety of crizotinib in patients with advanced NSCLC harboring MET alterations. This was a retrospective, multicenter (17 centers) study of Turkish Oncology Group. Patients' demographic, histological data, treatment, response rates, survival outcomes, and toxicity data were collected. Outcomes were presented for the study population and compared between MET alteration types. Total of 62 patients were included with a median age of 58.5 (range, 26-78). Major histological type was adenocarcinoma, and 3 patients (4.8%) had sarcomatoid component. The most common MET analyzing method was next generation sequencing (90.3%). MET amplification and mutation frequencies were 53.2% (n?=?33) and 46.8% (n?=?29), respectively. Overall response rate and disease control rate were 56.5% and 74.2% in whole study population, respectively. Median progression free survival (PFS) was 7.2 months (95% confidence interval [CI]: 3.8-10.5), and median overall survival (OS) was 18.7 months (95% CI: 13.7-23.7), regardless of treatment line. Median PFS was 6.1 months (95% CI: 5.6-6.4) for patients with MET amplification, whereas 14.3 months (95% CI: 6.7-21.7) for patients with MET mutation (P?=?.217). Median PFS was significantly longer in patients who have never smoked (P?=?.040), have good performance score (P?
  • Küçük Resim
    Öğe
    Real-world efficacy and safety of first-line nivolumab plus chemotherapy in patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: A nationwide observational Turkish Oncology Group (TOG) study
    (2024) Kutlu, Yasin; Dae, Shute Ailia; Yılmaz, Feride; Erdem, Dilek; Şendur, Mehmet Ali Nahit; Akbaş, Sinem; Şenocak Taşçı, Elif; Baş, Onur; Dane, Faysal; Sakin, Abdullah; Kaya, Ali Osman; Aykan, Musa Barış; Ergün, Yakup; Biter, Sedat; Dişel, Umut; Korkmaz, Mustafa; Selçukbiricik, Fatih; Köse, Fatih; Ölmez, Ömer Fatih; Bilici, Ahmet; Demir, Gökhan; Yalçın, Şuayib
    Based on the CheckMate 649 trial, nivolumab plus chemotherapy is the recommended first-line treatment for HER2-negative unresectable advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma. This nationwide, multicenter, retrospective study evaluated the real-world effectiveness of this regimen in Turkish patients and identified subgroups that may experience superior outcomes. Conducted across 16 oncology centers in Turkey, this study retrospectively reviewed the clinical charts of adult patients diagnosed with HER2-negative unresectable advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma from 2016 to 2023. This study included 111 patients (54 women, 57 men) with a median age of 58 years. The median progression-free survival (PFS) and overall survival (OS) were 11.7 months and 18.2 months, respectively, whereas the objective response rate (ORR) was 70.3%. Multivariable analyses revealed that previous curative surgery was a favorable independent prognostic factor for both PFS and OS. Conversely, an Eastern Cooperative Oncology Group performance status of 2 emerged as an adverse independent prognostic factor for OS. The safety profile of nivolumab plus chemotherapy was found to be manageable. Our findings support the use of nivolumab plus chemotherapy for the first-line treatment of Turkish patients with HER2-negative unresectable advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma. Patient selection based on clinical characteristics is crucial for optimizing treatment outcomes.
  • Küçük Resim
    Öğe
    The impact of hybrid capture-based comprehensive genomic profiling on treatment strategies in patients with solid tumors
    (Turkiye Klinikleri, 2022) Dişel, Umut; Köse, Fatih; Bilici, Ahmet; Özgüroğlu, Mustafa; Sağlam, Sezer; Şeker, Mesut; Aksoy, Sercan; Tek, İbrahim; Mandel, Nil Molinas; Demir, Gökhan; Arslan, Çağatay; Demiray, Mutlu; Öztürk, Mehmet Akif; Salepçi, Taflan; Eralp, Yeşim; Selçukbiricik, Fatih; Temizaş, Gökçe; Fidan, Ebru Gül
    Objective: The development of bioinformatics and comprehensive genomic profiling (CGP) has provided insights into the ap-plicability and functionality of the genomic alterations (GA). In this study, we evaluated the impact of CGP on the treatment plan and outcomes in a significant number of patients. Material and Methods: We carried out a retrospective case-control study on 164 adult patients with advanced solid tumors from 15 oncology centers in Türkiye. Results: In all cases, CGP was performed within 23.8 [standard deviation (SD)±32.1] months of initial diagnosis. Non-small cell lung carcinoma, breast cancer, unknown primary carcinoma, colorectal carcinoma, and sarcoma were among the most common tumor types, accounting for 61.5% of all cases. CGP was performed immediately after the diagnosis of advanced cancer in 13 patients (7.9%). In 158 patients (96.4%), at least one GA was found as per the CGP report. Also, in the reports, the average tumor mutational burden (TMB) and GAs were 7.3 (SD±8.7) mut/Mb and 3.5 (SD±2.0), respectively. According to CGP reports, 58 patients had 79 evidence-based drug suggestions for their particular tumor type, whereas 97 patients had 153 evidence-based drug suggestions for another tumor type. After the primary oncologist interpreted the CGP reports, significant changes were made to the treatment of 35 (21.3%) patients. Conclusion: We strongly believe that in the future, high-TMB or other tumor-agnostic biomarkers will become much more afford-able, and CGP will serve as one of the major decision-making tools for the treatment of patients along with pathological, radiological or lab-oratory tests.